Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Merus N.V. CS (NQ: MRUS ) 49.66 -1.27 (-2.49%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Merus N.V. CS < Previous 1 2 3 4 5 Next > 5 Analysts Have This to Say About Merus November 16, 2022 Via Benzinga Merus to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference November 09, 2022 From Merus N.V. Via GlobeNewswire Merus Announces Financial Results for the Third Quarter and Provides Business Update November 03, 2022 From Merus N.V. Via GlobeNewswire Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics October 26, 2022 From Merus N.V. Via GlobeNewswire What 4 Analyst Ratings Have To Say About Merus October 13, 2022 Within the last quarter, Merus (NASDAQ:MRUS) has observed the following analyst ratings: Via Benzinga 4 Analysts Have This to Say About Merus October 13, 2022 Within the last quarter, Merus (NASDAQ:MRUS) has observed the following analyst ratings: Via Benzinga Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus January 26, 2022 Incyte Corporation (NASDAQ: INCY) is Via Benzinga Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday November 04, 2022 Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) shares jumped 242.8% to close at $105.72 on Thursday. The company announced a strategic plan to enter into the clean energy industry. Via Benzinga Why Lincoln National Shares Are Trading Lower By 31%? Here Are 72 Stocks Moving In Thursday's Session November 03, 2022 Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) gained 64% to $50.60. Via Benzinga Albemarle To Rally Around 8%? Here Are 5 Other Price Target Changes For Thursday October 13, 2022 Berenberg raised Albemarle Corporation (NYSE: ALB) price target from $260 to $270. Berenberg analyst Andres Castanos Mollor downgraded the stock from Buy to Hold. Albemarle shares fell 7.9% to close at... Via Benzinga Why New Oriental Education Shares Jumped Over 28%; Here Are 68 Biggest Movers From Yesterday October 27, 2022 Gainers ESSA Pharma Inc. (NASDAQ: EPIX) shares climbed 180.2% to close at $4.82 on Wednesday after the company highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At the... Via Benzinga Analyst Casts Doubts On Merus' Lung Candidate Safety Profile October 12, 2022 Earlier today, Merus N.V. (NASDAQ: MRUS) announced the publication of the abstract highlighting interim data from the ongoing phase 1/2 trial of the bispecific antibody MCLA-129 in advanced non-small... Via Benzinga Why Seagate Shares Are Trading Lower By More Than 7%? Here Are 49 Stocks Moving In Wednesday's Mid-Day Session October 26, 2022 Gainers ESSA Pharma Inc. (NASDAQ: EPIX) shares surged 59.3% to $2.7417 after the company highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At the 29th Annual Prostate... Via Benzinga Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics October 12, 2022 From Merus N.V. Via GlobeNewswire Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2022 August 02, 2022 Upgrades Via Benzinga Merus Stock Joins Rank Of Stocks With RS Ratings Over 90 July 14, 2022 On Thursday, Netherlands-based Merus stock had its Relative Strength (RS) Rating upgraded to 94 from 78 a day earlier. Via Investor's Business Daily Needham Says Merus' ASCO Update On Zeno 'Positive' June 06, 2022 Needham writes that Merus NV (NASDAQ: MRUS) has enough data to initiate an FDA marketing application filing in mid-2022 after presenting Zenocutuzumab (Zeno) data in NRG1-fusion (NRG1+) Cancer. Via Benzinga 7 Top-Rated Biotech Stocks to Buy for Q2 April 21, 2022 In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill. Via InvestorPlace 70 Biggest Movers From Friday May 31, 2022 Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022 February 10, 2022 Upgrades According to Gordon Haskett, the prior rating for Williams-Sonoma Inc (NYSE:WSM) was changed from Hold to Accumulate. Williams-Sonoma earned $3.32 in the third quarter,... Via Benzinga Promising Developments in Breast Cancer Treatments Ahead in 2022 January 12, 2022 FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 12, 2022 – USA News Group – So far in 2022, there have already been some impressive developments in the battle against... Via FinancialNewsMedia Merus Shares Updated Data From Zeno Triplet Combo Data In Breast Cancer Settings December 10, 2021 Merus NV (NASDAQ: MRUS) has presented updated data on zenocutuzumab (Zeno) combined with trastuzumab and vinorelbine in HER2 positive/amplified (HER2+) metastatic... Via Benzinga The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill November 05, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus NRx's COVID-19 Drug Fails to Get Authorization From FDA Due To... Via Benzinga Exposures COVID-19 Product Safety The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More December 06, 2021 The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... Via Benzinga Exposures Product Safety Notable Merus Insider Makes $31M Sale October 11, 2021 Mark Lampert, 10% Owner at Merus (NASDAQ:MRUS), made a large insider sell on October 8, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and... Via Benzinga Topics Regulatory Compliance Exposures Legal Regulatory The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology October 12, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... Via Benzinga Exposures COVID-19 45 Biggest Movers From Yesterday October 08, 2021 Gainers Camber Energy, Inc.. (NYSE: CEI) shares surged 95.9% to close at $1.78 on Thursday after dipping over 40% on Wednesday. Camber Energy filed amended 8K showing financial... Via Benzinga Mid-Afternoon Market Update: Crude Oil Rises 1%; New Fortress Energy Shares Spike Higher October 07, 2021 Toward the end of trading Thursday, the Dow traded up 1.29% to 34,860.01 while the NASDAQ rose 1.47% to 14,714.54. The S&P also rose, gaining 1.22% to 4,416.63. The U.S. has... Via Benzinga Topics Stocks Exposures Fossil Fuels US Equities Merus Stock Flirts With Breakout After Experimental Drug Shrinks All Tumors October 07, 2021 Merus is flirting with a buy point on its strong, early-stage cancer test results. Via Investor's Business Daily Mid-Day Market Update: Dow Jumps Over 500 Points; Osmotica Pharmaceuticals Shares Slide October 07, 2021 Midway through trading Thursday, the Dow traded up 1.51% to 34,938.25 while the NASDAQ rose 1.64% to 14,739.43. The S&P also rose, gaining 1.41% to 4,425.22. The U.S. has the... Via Benzinga Topics Stocks Exposures US Equities < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
